2010
Interferon-beta inhibits Th17 cell differentiation in patients with multiple sclerosis.
Ramgolam V, Markovic-Plese S. Interferon-beta inhibits Th17 cell differentiation in patients with multiple sclerosis. Endocrine Metabolic & Immune Disorders - Drug Targets 2010, 10: 161-7. PMID: 20384573, DOI: 10.2174/187153010791213029.Peer-Reviewed Original ResearchConceptsDendritic cellsT cellsB cellsMultiple sclerosisCell-mediated autoimmune responseRetinoic acid-related orphan receptorTranscription factor retinoic acid-related orphan receptorAcid-related orphan receptorCytokines IL-17AFirst-line therapyCytokines IL-1bInduction of suppressorCell differentiationMechanism of actionRR-MSIL-17AIL-23Th17 cellsIL-10Immunoregulatory mechanismsIL-12Autoimmune responseAutoimmune diseasesCytokines interleukinChemokine receptors
2008
Simvastatin Inhibits IL-17 Secretion by Targeting Multiple IL-17-Regulatory Cytokines and by Inhibiting the Expression of IL-17 Transcription Factor RORC in CD4+ Lymphocytes
Zhang X, Jin J, Peng X, Ramgolam V, Markovic-Plese S. Simvastatin Inhibits IL-17 Secretion by Targeting Multiple IL-17-Regulatory Cytokines and by Inhibiting the Expression of IL-17 Transcription Factor RORC in CD4+ Lymphocytes. The Journal Of Immunology 2008, 180: 6988-6996. PMID: 18453621, DOI: 10.4049/jimmunol.180.10.6988.Peer-Reviewed Original ResearchMeSH KeywordsBlotting, WesternCD4-Positive T-LymphocytesCytokinesEnzyme-Linked Immunosorbent AssayFemaleFlow CytometryGene ExpressionHumansImmunologic FactorsInterleukin-17MaleMonocytesMultiple SclerosisNuclear ProteinsOligonucleotide Array Sequence AnalysisReceptors, Cytoplasmic and NuclearReverse Transcriptase Polymerase Chain ReactionSimvastatinSuppressor of Cytokine Signaling 3 ProteinSuppressor of Cytokine Signaling ProteinsT-Lymphocyte SubsetsConceptsAutoimmune responseMultiple sclerosisImmunomodulatory mechanismsT cellsIL-23 gene expressionTranscription factor RORCIL-17 productionIL-17 secretionIL-27 productionChronic inflammatory diseaseNovel immunomodulatory mechanismGood safety profileIL-17 transcriptionPromising therapeutic approachCholesterol-lowering agentsHuman autoimmune responseImmunomodulatory agentsSafety profileAutoimmune diseasesIL-6IL-4Inflammatory diseasesSpecific effectsTherapeutic approachesIFN-gamma